Add like
Add dislike
Add to saved papers

Accuracy of sonographically estimated fetal weight with and without oligohydramnios. A case-control study.

OBJECTIVE: To determine the accuracy of sonographically estimated fetal weight among women with and without oligohydramnios (amniotic fluid index [AFI] < or = 5.0 cm) and to ascertain the ability to detect fetal growth restriction (FGR) (estimated birth weight < 10th percentile for gestational age [GA]) among patients in two groups.

STUDY DESIGN: Assuming that 50% of sonographic predictions are within 10% of the birth weight in the study group, 300 parturients are necessary to show a difference of 15% among controls (alpha = .05, beta = .02). The study group consisted of parturients with a reliable GA of > or = 24, no known anomalies and known AFI of < or = 5.0 cm. The control (1:1) was the next patient with the same GA but AFI between 5.1 and 23.9 cm. The paired t test was used, and the odds ratio (OR) and 95% confidence interval (CI) were calculated. P < .05 was considered significant.

RESULTS: Among the study and control groups (N = 162 each), maternal demographics, mean estimate (P = .078) and actual birth weight (P = .091) were similar. Sonographic estimates within 10% of weight were not significantly different among those with (57%) and without oligohydramnios (59%; OR 0.92; 95% CI 0.59, 1.44). The frequency of FGR was higher among those with inadequate fluid (18%) than controls (9%; OR 2.13; 95% CI 1.10, 4.16). Sensitivity, positive predictive value and likelihood ratio were higher among those with oligohydramnios (76%, 78% and 16) than controls (53%, 42% and 7).

CONCLUSION: The accuracy of sonographic estimates of fetal weight is not influenced by whether the parturient has oligohydramnios. Moreover, the accuracy of identifying FGR is not diminished among those with AFI < or = 5.0 versus > 5.0 cm.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app